Drug Res (Stuttg) 2020; 70(04): 145-150
DOI: 10.1055/a-1095-5418
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Involvement of NO in Antinociception of NSAIDS in Murine Formalin Hind Paw Assay

Viviana Noriega
1   Universidad de Chile, Facultad de Medicina, Hospital Clinico, Cardiovascular Department, Santiago, Chile
,
Hugo F. Miranda
2   Universidad de Chile, Facultad de Medicina, Neuroscience, Santiago, Chile
,
Juan Carlos Prieto
3   Universidad de Chile, Facultad de Medicina, Pharmacology, Santiago, Chile
,
Ramón Sotomayor-Zárate
4   Universidad de Valparaíso, Instituto de Fisiología, Valparaíso, Chile
,
Fernando Sierralta
3   Universidad de Chile, Facultad de Medicina, Pharmacology, Santiago, Chile
› Author Affiliations
Funding: No funding to support the research of this article.
Further Information

Publication History

received 13 December 2019

accepted 13 January 2020

Publication Date:
30 January 2020 (online)

Abstract

There are different animal models to evaluate pain among them the formalin hind paw assay which is widely used since some of its events appear to be similar to the clinical pain of humans. The assay in which a dilute solution of formalin is injected into the dorsal hindpaw of a murine produces two ‘phases’ of pain behavior separated by a inactive period. The early phase (Phase I) is probably due to direct activation of nociceptors and the second phase (Phase II) is due to ongoing inflammatory input and central sensitization. Mice were used to determine the potency antinociceptive of piroxicam (1,3,10,and 30 mg/kg), parecoxib (0.3, 1,3,10 and 30 mg/kg), dexketoprofen (3,10,30 and 100 mg/kg) and ketoprofen (3,10,30 and 100 mg/kg). Dose-response for each NSAIDs were created before and after 5 mg/kg of L-NAME i.p. or 5 mg/kg i.p. of 7-nitroindazole. A least-squares linear regression analysis of the log dose–response curves allowed the calculation of the dose that produced 50% of antinociception (ED50) for each drug. The ED50 demonstrated the following rank order of potency, in the phase I: piroxicam > dexketoprofen > ketoprofen > parecoxib and in the phase II: piroxicam > ketoprofen > parecoxib > dexketoprofen. Pretreatment of the mice with L-NAME or 7-nitroindazol induced a significant increase of the analgesic power of the NSAIDs, with a significant reduction of the ED50. It is suggested that NO may be involved in both phases of the trial, which means that nitric oxide regulates the bioactivity of NSAIDs.

 
  • References

  • 1 Barrot M. Tests and models of nociception and pain in rodents. Neuroscience 2012; 211: 39-50
  • 2 Dubuisson D, Dennis SG. The formalin test: A quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain 1977; 4: 161-174
  • 3 Tjølsen A, Berge OG, Hunskaar S. et al. The formalin test: An evaluation of the method. Pain 1992; 51: 5-17
  • 4 Furst S. Transmitters involved in antinociception in the spinal cord. Brain Res Bull 1999; 48: 129-141
  • 5 Miclescu A, Gordh T. Nitric oxide and pain: ‘Something old, something new’ Acta Anaesthesiol Scand. 2009; 53: 1107-1120
  • 6 Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthase: Structure, function and inhibition. Biochem J 2001; 357: 593-615
  • 7 Sousa AM, Prado WA. The dual effect of a nitric oxide donor in nociception. Brain Res 2001; 897: 9-19
  • 8 Paul-Clark MJ, Gilroy DW, Willis D. et al. Nitric xide synthase inhibitors have opposite effects on acute inflammation depending on their route of administration. J Immunol 2001; 166: 1169-1177
  • 9 Moore PK, Oluyomi AO, Babbedge RC. et al. L-NG- nitro arginine methyl ester exhibits antinociceptive activity in the mouse. Br J Pharmacol 1991; 102: 198-202
  • 10 Moore PK, Wallace P, Gaffen Z. et al. Characterization of the novel nitric oxide synthase inhibitor 7-nitroindazole and related indazoles: Antinociceptive and cardiovascular effects. Br J Pharmacol 1993; 110: 219-224
  • 11 Malmberg AB, Yaksh TL. Spinal nitric oxide synthesis inhibition blocks NMDA-induced thermal hyperalgesia and produces antinociception in the formalin test in rats. Pain 1993; 54: 291-300
  • 12 Duarte ID, Ferreira SH. L-NAME causes antinociception by stimulation of the arginine-NO-cGMP pathway. Mediators Inflamm 2000; 9: 25-30
  • 13 Doursout MF, Liang Y, Chelly JE. NOS inhibitors exhibit antinociceptive properties in the rat formalin test. Can J Anaesth 2003; 50: 909-916
  • 14 Sakurada C, Sugiyama A, Nakayama M. et al. Antinociceptive effect of spinally injected L-NAME on the acute nociceptive response induced by low concentrations of formalin. Neurochem Int 2001; 38: 417-423
  • 15 Miranda HF, Puig MM, Dursteler C. et al. Dexketoprofen-induced antinociception in animal models of acute pain: Synergy with morphine and paracetamol. Neuropharmacology 2007; 52: 291-296
  • 16 Moore PK, Wallace P, Gaffen Z. et al. Characterization of the novel nitric oxide synthase inhibitor 7-nitro indazole and related indazoles: Antinociceptive and cardiovascular effects.Br. J. Pharmacol 1993; 110: 219-224
  • 17 Zhao YQ, Wang HY, Yin JB. et al. The analgesic effects of celecoxib on the formalin-induced short- and long-term inflammatory pain. Pain Physician 2017; 20: 575-584
  • 18 Talarek S, Fidecka S. Role of nitric oxide in benzodiazepines-induced antinociception in mice. Pol J Pharmacol 2002; 54: 27-34
  • 19 Mehanna MM, Domiati S, Nakkash Chmaisse H. et al. Antinociceptive effect of tadalafil in various pain models: Involvement of opioid receptors and nitric oxide cyclic GMP pathway. Toxicol Appl Pharmacol 2018; 352: 170-175
  • 20 Gupta R, Gupta LK, Bhattacharya SK. Chronic administration of modafinil induces hyperalgesia in mice: Reversal by L-NG-nitro- arginine methyl ester and 7-nitroindazole. Eur J Pharmacol 2014; 736: 95-100
  • 21 Aguirre-Bañuelos P, Granados-Soto V. Evidence for the participation of the nitric oxide-cyclic GMP pathway in the antinociceptive action of meloxicam in the formalin test. Eur J Pharmacol 2000; 395: 9-13
  • 22 Ortiz MI, Granados-Soto V, Castañeda-Hernández G. The NO-cGMP-K+ channel pathway participates in the antinociceptive effect of diclofenac, but not of indomethacin. Pharmacol Biochem Behav 2003; 76: 187-195
  • 23 Ghorbanzadeh B, Kheirandish V, Mansouri MT. Involvement of the L-arginine/Nitric Oxide/Cyclic GMP/KATP Channel Pathway and PPARγ Receptors in the Peripheral Antinociceptive Effect of Carbamazepine. Drug Res (Stuttg). 2019; DOI: 10.1055/a-0959-5896.
  • 24 Bujalska-Zadrożny M, Wolińska R, Leśniak A. et al. Central antinociceptive effect of tapentadol is increased by nitric oxide synthase inhibitors. Behav Pharmacol 2016; 27: 606-614
  • 25 Rangel RA, Marinho BG, Fernandes PD. et al Pharmacological mechanisms involved in the antinociceptive effects of dexmedetomidine in mice. Fundam Clin Pharmacol 2014; 28: 104-113
  • 26 Dudhgaonkar SP, Kumar D, Naik A. et al. Interaction of inducible nitric oxide synthase and cyclooxygenase-2 inhibitors in formalin-induced nociception in mice. Eur J Pharmacol 2004; 492: 117-122
  • 27 Dableh LJ, Henry JL. The selective neuronal nitric oxide synthase inhibitor 7-nitroindazole has acute analgesic but not cumulative effects in a rat model of peripheral neuropathy. J Pain Res 2011; 4: 85-90
  • 28 Romero TR, Resende LC, Duarte ID. The neuronal NO synthase participation in the peripheral antinociception mechanism induced by several analgesic drugs. Nitric Oxide 2011; 25: 431-435
  • 29 Hamza M, Dionne RA. Mechanisms of Non-Opioid Analgesics Beyond Cyclooxygenase Enzyme Inhibition. Curr Mol Pharmaco 2009; 2: 1-14
  • 30 Miranda HugoF., Noriega Viviana, Sierralta Fernando. et al. Non-steroidal anti-inflammatory drugs in tonic, phasic and inflammatory mouse models: Drug Research. 2019; DOI: 10.1055/a-0956-673.